Showing results (401-410 of 651) with videos related to

Sort By:
Pageof 66
Glomerular Diseases|August 15, 2024
Effects of Dapagliflozin in Patients with Membranous NephropathyGlenn M Chertow, Hiddo Lambers Heerspink, Patrick B Mark, et al.
The New England Journal of Medicine|May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesVlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 23, 2026
Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trialBrian Rayner, Kenneth W Mahaffey, Johannes F E Mann, et al.
Diabetes & Vascular Disease Research|January 3, 2019
Cardiac ventricular sizes are reduced in patients with long-term, normoalbuminuric type 1 diabetes compared to the non-diabetic background populationHenrik Ø Hjortkjær, Tonny Jensen, Jannik Hilsted, et al.
Plos One|October 15, 2008
Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized studySøren Søgaard Lund, Lise Tarnow, Anne Sofie Astrup, et al.
American Journal of Preventive Cardiology|July 6, 2026
Impact of air pollution exposure on chronic kidney disease and type 2 diabetes: A FIDELITY analysisSadeer Al-Kindi, Zhuo Chen, Jean-Eudes Dazard, et al.
The International Journal of Cardiovascular Imaging|October 20, 2021
Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trialMads Ersbøll, Mikkel Jürgens, Philip Hasbak, et al.
Frontiers in Endocrinology|December 19, 2022
Multiomics signatures of type 1 diabetes with and without albuminuriaMarc Clos-Garcia, Tarunveer S Ahluwalia, Signe A Winther, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 12, 2021
Non-invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controlsIda K B Rasmussen, Philip Hasbak, Bernt J von Scholten, et al.
Diabetes, Obesity & Metabolism|October 4, 2022
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist usePeter Rossing, Rajiv Agarwal, Stefan D Anker, et al.
Pageof 66